Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Univar Solutions
Univar Solutions
(UNVR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Cufence
Trientine
2019-07-25
Hepatolenticular degeneration
,
Nervous system heavy metal poisoning
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Trientine
melanoma
,
neoplasms
,
macular edema
,
hypertrophic cardiomyopathy
,
cardiomyopathies
,
hypertrophy
,
vitamin d deficiency
,
respiratory tract infections
,
respiratory tract diseases
,
anemia
,
sickle cell anemia
,
lung diseases
,
respiration disorders
,
asthma
,
acute chest syndrome
,
nutrition disorders
,
hemolytic anemia
,
vitamin a deficiency
,
hemolytic anemia congenital
,
deficiency diseases
,
ovarian neoplasms
,
fallopian tube neoplasms
,
ovarian epithelial carcinoma
,
peritoneal neoplasms
,
type 2 diabetes mellitus
,
cataract
,
diabetes mellitus
,
edema
,
capsule opacification
,
hepatolenticular degeneration
,
retinal diseases
,
diabetic retinopathy
Trientine dihydrochloride
hypertrophic cardiomyopathy
,
cardiomyopathies
,
hypertrophy
,
hepatolenticular degeneration
Trientine hydrochloride
hypertrophic cardiomyopathy
,
cardiomyopathies
,
hypertrophy
,
hepatolenticular degeneration
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use